Amlodipine increases risk of primary open-angle glaucoma
The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken...
Saved in:
Published in | Clinical hypertension Vol. 30; no. 1; p. 33 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central
01.11.2024
대한고혈압학회 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed.
We used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma.
Amlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% (P = 0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine.
Amlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG.
None. |
---|---|
AbstractList | The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed.We used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma.
Amlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% (
P
= 0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine.
Amlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG.None. Background The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed.
Methods We used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma.
Results Amlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% (P=0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine.
Conclusions Amlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG. KCI Citation Count: 0 The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed.BACKGROUNDThe use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed.We used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma.METHODSWe used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma.Amlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% (P = 0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine.RESULTSAmlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% (P = 0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine.Amlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG.CONCLUSIONSAmlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG.None.TRIAL REGISTRATIONNone. BackgroundThe use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed.MethodsWe used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma.ResultsAmlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% (P = 0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine.ConclusionsAmlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG.Trial registrationNone. The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed. We used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma. Amlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% (P = 0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine. Amlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG. None. |
Author | Rheinstein, Peter H. Lehrer, Steven |
Author_xml | – sequence: 1 givenname: Steven orcidid: 0000-0002-4850-094X surname: Lehrer fullname: Lehrer, Steven organization: Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY USA – sequence: 2 givenname: Peter H. surname: Rheinstein fullname: Rheinstein, Peter H. organization: Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39482785$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003134795$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp9kUtLBDEQhIMovv-ABxnwIsJo5znJcRFfIAii55DJZpa4M8mazBz890Z3BfHgqfvwVdFddYC2QwwOoRMMlxhLcZUZSMlrIKwGIApqtYX2CXBRcwVq-9e-h45zfgMAzLlSIHbRHlVMkkbyfSRnQx_nfuWDq3ywyZnscpV8Xlaxq1bJDyZ9VHHlQm3ConfVojeTjYM5Qjud6bM73sxD9Hp783J9Xz8-3T1czx5ryzCMNWG8cY3ApJPccMdaxuaiVdZxKhSbd0ZCqygxWFpguG2xI9A1naEcW4mFoYfoYu0bUqeX1uto_PdcRL1Mevb88qAxCEYajgt8voZXKb5PLo968Nm6vjfBxSlrigmFhlMmCnr2B32LUwrlFU1JiUow1dBCnW6oqR3cXG8C0T8BFkCuAZtizsl12vrRjD6GMRnfl9P0V116XZcudenvurQqUvJH-uP-j-gTUEWTxg |
CitedBy_id | crossref_primary_10_7759_cureus_74976 |
Cites_doi | 10.1186/s13742-015-0047-8 10.2165/11204420-000000000-00000 10.1093/function/zqad047 10.1016/S0140-6736(13)61752-3 10.1371/journal.pgen.1002611 10.2165/00002018-200730060-00009 10.1016/j.ophtha.2023.05.001 10.1186/s13041-016-0238-y 10.1001/jama.1993.03500210065033 10.1001/jamaophthalmol.2023.3877 10.1038/s41588-018-0176-y 10.1038/s41433-019-0603-z 10.1111/j.1360-0443.2009.02504.x 10.1016/j.ophtha.2018.01.007 10.1136/bjo.2004.053397 10.1097/IJG.0000000000001118 10.1007/s40264-015-0333-5 10.1007/s11682-021-00548-y 10.1093/jnci/djz241 10.1016/j.ophtha.2015.11.031 10.1038/nbt.2113 10.1167/iovs.61.11.25 10.1002/pds.677 10.1371/journal.pone.0157753 |
ContentType | Journal Article |
Copyright | 2024. The Author(s). 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2024. The Author(s). – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI 7X8 ACYCR |
DOI | 10.1186/s40885-024-00290-9 |
DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central Database Suite (ProQuest) ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic Korean Citation Index |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2056-5909 |
EndPage | 33 |
ExternalDocumentID | oai_kci_go_kr_ARTI_10642751 39482785 10_1186_s40885_024_00290_9 |
Genre | Journal Article |
GeographicLocations | United Kingdom--UK United States--US |
GeographicLocations_xml | – name: United Kingdom--UK – name: United States--US |
GroupedDBID | 0R~ 5-W 5VS 8JR AAFWJ AAYXX ACGFS ADBBV ADRAZ ADUKV AFPKN AHBYD AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG BAWUL BCNDV BFQNJ BMC C6C CITATION DIK EBS EF. EJD GROUPED_DOAJ H13 HYE IAO IHR IHW ITC KQ8 M48 M~E OK1 PGMZT RBZ ROL RPM RSV SOJ NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AHMBA ALIPV AZQEC BENPR BPHCQ BVXVI CCPQU DWQXO FYUFA HMCUK K9. MOJWN PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PROAC UKHRP 7X8 ACYCR |
ID | FETCH-LOGICAL-c410t-2457e7612f85a5e4b44d6b9ce53694dfa80b932a18c041bb1e20f7fa351c816a3 |
IEDL.DBID | 7X7 |
ISSN | 2056-5909 1342-2154 2635-6325 |
IngestDate | Thu Jul 24 03:28:46 EDT 2025 Fri Jul 11 03:20:12 EDT 2025 Mon Jun 30 10:54:07 EDT 2025 Mon Jul 21 06:02:24 EDT 2025 Sun Jul 06 05:07:11 EDT 2025 Thu Apr 24 23:10:13 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Glaucoma Systemic medication Epidemiology Intraocular pressure |
Language | English |
License | 2024. The Author(s). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c410t-2457e7612f85a5e4b44d6b9ce53694dfa80b932a18c041bb1e20f7fa351c816a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 https://clinicalhypertension.biomedcentral.com/articles/10.1186/s40885-024-00290-9 |
ORCID | 0000-0002-4850-094X |
OpenAccessLink | https://www.proquest.com/docview/3201564973?pq-origsite=%requestingapplication% |
PMID | 39482785 |
PQID | 3201564973 |
PQPubID | 2040145 |
PageCount | 1 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10642751 proquest_miscellaneous_3123075346 proquest_journals_3201564973 pubmed_primary_39482785 crossref_citationtrail_10_1186_s40885_024_00290_9 crossref_primary_10_1186_s40885_024_00290_9 |
PublicationCentury | 2000 |
PublicationDate | 2024-11-01 |
PublicationDateYYYYMMDD | 2024-11-01 |
PublicationDate_xml | – month: 11 year: 2024 text: 2024-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Clinical hypertension |
PublicationTitleAlternate | Clin Hypertens |
PublicationYear | 2024 |
Publisher | BioMed Central 대한고혈압학회 |
Publisher_xml | – name: BioMed Central – name: 대한고혈압학회 |
References | van Koolwijk (10.1186/s40885-024-00290-9_ref17) 2012; 8 Arthur (10.1186/s40885-024-00290-9_ref12) 2020; 112 Zhang (10.1186/s40885-024-00290-9_ref20) 2016; 9 Curran (10.1186/s40885-024-00290-9_ref3) 2010; 70 Agrawal (10.1186/s40885-024-00290-9_ref18) 2009; 104 Böhm (10.1186/s40885-024-00290-9_ref8) 2012; 30 Kessler (10.1186/s40885-024-00290-9_ref6) 1993; 269 Zheng (10.1186/s40885-024-00290-9_ref24) 2018; 125 Böhm (10.1186/s40885-024-00290-9_ref9) 2016; 11 Lawrence (10.1186/s40885-024-00290-9_ref16) 2021; 15 Chan (10.1186/s40885-024-00290-9_ref14) 2016; 123 Chang (10.1186/s40885-024-00290-9_ref15) 2015; 4 10.1186/s40885-024-00290-9_ref4 Wu (10.1186/s40885-024-00290-9_ref23) 2020; 34 Lehrer (10.1186/s40885-024-00290-9_ref19) 2022; 14 Hauben (10.1186/s40885-024-00290-9_ref27) 2007; 30 Evans (10.1186/s40885-024-00290-9_ref11) 2001; 10 Mahmood (10.1186/s40885-024-00290-9_ref13) 2014; 383 Vergroesen (10.1186/s40885-024-00290-9_ref1) 2023; 130 Lehrer (10.1186/s40885-024-00290-9_ref7) 2019; 28 Langman (10.1186/s40885-024-00290-9_ref26) 2005; 89 Kastner (10.1186/s40885-024-00290-9_ref22) 2023; 141 Asefa (10.1186/s40885-024-00290-9_ref25) 2020; 61 Coloma (10.1186/s40885-024-00290-9_ref10) 2015; 38 Bird (10.1186/s40885-024-00290-9_ref5) 2023; 4 MacGregor (10.1186/s40885-024-00290-9_ref21) 2018; 50 Khawaja (10.1186/s40885-024-00290-9_ref2) 2019; 28 |
References_xml | – volume: 4 start-page: 7 year: 2015 ident: 10.1186/s40885-024-00290-9_ref15 publication-title: Gigascience doi: 10.1186/s13742-015-0047-8 – volume: 70 start-page: 191 year: 2010 ident: 10.1186/s40885-024-00290-9_ref3 publication-title: Drugs doi: 10.2165/11204420-000000000-00000 – volume: 4 start-page: zqad047 year: 2023 ident: 10.1186/s40885-024-00290-9_ref5 publication-title: Function (Oxf) doi: 10.1093/function/zqad047 – volume: 383 start-page: 999 year: 2014 ident: 10.1186/s40885-024-00290-9_ref13 publication-title: Lancet doi: 10.1016/S0140-6736(13)61752-3 – volume: 8 start-page: e1002611 year: 2012 ident: 10.1186/s40885-024-00290-9_ref17 publication-title: PLoS Genet doi: 10.1371/journal.pgen.1002611 – volume: 30 start-page: 551 year: 2007 ident: 10.1186/s40885-024-00290-9_ref27 publication-title: Drug Saf doi: 10.2165/00002018-200730060-00009 – volume: 130 start-page: 893 year: 2023 ident: 10.1186/s40885-024-00290-9_ref1 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2023.05.001 – volume: 9 start-page: 54 year: 2016 ident: 10.1186/s40885-024-00290-9_ref20 publication-title: Mol Brain doi: 10.1186/s13041-016-0238-y – volume: 269 start-page: 2765 year: 1993 ident: 10.1186/s40885-024-00290-9_ref6 publication-title: JAMA doi: 10.1001/jama.1993.03500210065033 – volume: 141 start-page: 956 year: 2023 ident: 10.1186/s40885-024-00290-9_ref22 publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2023.3877 – volume: 50 start-page: 1067 year: 2018 ident: 10.1186/s40885-024-00290-9_ref21 publication-title: Nat Genet doi: 10.1038/s41588-018-0176-y – volume: 34 start-page: 12 year: 2020 ident: 10.1186/s40885-024-00290-9_ref23 publication-title: Eye (Lond) doi: 10.1038/s41433-019-0603-z – volume: 104 start-page: 518 year: 2009 ident: 10.1186/s40885-024-00290-9_ref18 publication-title: Addiction doi: 10.1111/j.1360-0443.2009.02504.x – volume: 125 start-page: 984 year: 2018 ident: 10.1186/s40885-024-00290-9_ref24 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2018.01.007 – volume: 89 start-page: 960 year: 2005 ident: 10.1186/s40885-024-00290-9_ref26 publication-title: Br J Ophthalmol doi: 10.1136/bjo.2004.053397 – volume: 28 start-page: 205 year: 2019 ident: 10.1186/s40885-024-00290-9_ref7 publication-title: Discov Med – volume: 28 start-page: e49 year: 2019 ident: 10.1186/s40885-024-00290-9_ref2 publication-title: J Glaucoma doi: 10.1097/IJG.0000000000001118 – volume: 38 start-page: 921 year: 2015 ident: 10.1186/s40885-024-00290-9_ref10 publication-title: Drug Saf doi: 10.1007/s40264-015-0333-5 – volume: 15 start-page: 2813 year: 2021 ident: 10.1186/s40885-024-00290-9_ref16 publication-title: Brain Imaging Behav doi: 10.1007/s11682-021-00548-y – volume: 112 start-page: 893 year: 2020 ident: 10.1186/s40885-024-00290-9_ref12 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djz241 – volume: 123 start-page: 771 year: 2016 ident: 10.1186/s40885-024-00290-9_ref14 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2015.11.031 – volume: 30 start-page: 137 year: 2012 ident: 10.1186/s40885-024-00290-9_ref8 publication-title: Nat Biotechnol doi: 10.1038/nbt.2113 – volume: 61 start-page: 25 year: 2020 ident: 10.1186/s40885-024-00290-9_ref25 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.61.11.25 – ident: 10.1186/s40885-024-00290-9_ref4 – volume: 10 start-page: 483 year: 2001 ident: 10.1186/s40885-024-00290-9_ref11 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.677 – volume: 14 start-page: e23919 year: 2022 ident: 10.1186/s40885-024-00290-9_ref19 publication-title: Cureus – volume: 11 start-page: e0157753 year: 2016 ident: 10.1186/s40885-024-00290-9_ref9 publication-title: PLoS ONE doi: 10.1371/journal.pone.0157753 |
SSID | ssj0001559906 ssj0001853425 ssib042018900 |
Score | 2.273089 |
Snippet | The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who... BackgroundThe use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general,... |
SourceID | nrf proquest pubmed crossref |
SourceType | Open Website Aggregation Database Index Database Enrichment Source |
StartPage | 33 |
SubjectTerms | Biobanks Chromosomes Cornea FDA approval Genomes Glaucoma Optic nerve 내과학 |
SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LS-RAEC5GhWUv4nONLyLrTXpNT7qT7oOIiIMKsycHvDWdpFvEMdF5gP57q_IYEHTZUw7patL1SH1FdVUBHFPHk9xqiUEOtwyVQqLNiZQlhbXOS2-FoELh4d_keiRu7-V9D7pxRy0Dp1-GdjRPajQZ_3l7fT9Hgz-rDV4lp1OBpkJ1xoJRkilieglW0DOlZKjDFu43VcMSf771vDn0-0zqSHd1NF9u88lXLZUT_z0Mrd3RYA1WWxwZXjSCX4eeKzfgx7DNlG-CungeVwUNpnbhY0nQcOqmIV0kDysfvjQ9JkI6K7Plw9iFCKPnqH12C0aDq7vLa9ZOSWC54NGM9YVMXYpAxStppROZEEWS6dzJONGi8FZFGYI0y1UeCZ5l3PUjn3obS54rnth4G5bLqnQ7EGplU1nwDENCKZBaeZRWkSPkKwrEOVEAvOOHydsW4jTJYmzqUEIlpuGhQR6amodGB3CyoGkP98_Vv5HN5il_NNT3mp4PlXmaGET3N0iH0VIqeQD7nRhMpzEm7lNVuNBpHMDR4jUaC2VAbOmqOa7hdO9dxiIJ4FcjvsVHxZo6oiq5-x_Ue_CzT3pS1yTuw_JsMncHCE5m2WGtcR-3y9n4 priority: 102 providerName: Scholars Portal |
Title | Amlodipine increases risk of primary open-angle glaucoma |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39482785 https://www.proquest.com/docview/3201564973 https://www.proquest.com/docview/3123075346 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003134795 |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Clinical Hypertension, 2024, 30(0), , pp.33-33 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB4VuPRSteorLV2lam-VRbwZx84JQQWilUAVKtKqF8vxAyGWhG52_z8z2eyiHsrFOcSO4nnY39jzAPjKGU-8qxUZOdIJEgpFOodaVMG5mFRyiBwofH5RnV3hz5majQdu_ehWuVkTh4U6dJ7PyA_KKQf9Yq3Lw_u_gqtG8e3qWEJjB_Y4dRm7dOmZfjxjob0Ih7qrsuQoFIILm7gZUx30SBrG4cko-G6qEPU_e9NOu0j_h53D9nP6El6MuDE_WjP6FTyL7WswR3fzLnD16ZjftIz_-tjn7C2edym_XyeSyLlAlnDt9TzmhJVXNF33Bq5OT35_PxNjKQThURZLMUWloyY0koxyKmKDGKqm9lGVVY0hOVM0hMScNL5A2TQyToukkyuV9EZWrnwLu23XxveQ18ZpFWRDdp9CGm0SsSR4wnUhEJgpMpAbIlg_5gnnchVzO9gLprJrwlkinB0IZ-sMvm3HjJN7svcXoq299TeWk1vz87qztwtLEP4HjSOTSCuZwf6G9nbUq94-SkEGn7evSSP4msO1sVtRH8nO7cT5KoN3a55tf6qsOe2pUR-e_vhHeD5luRhiDvdhd7lYxU8EPpbNZJCwCewdn1z8upwMJjy152iovTz-8wAs49Xu |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Nb9QwEB212wNcEBVfKaUYAScUNU7sxDmgqkCrXdquEGql3oxjO1XVJSmbXSH-FL-xM_nYigO99ZRDbCt5Htvv2Z4ZgHcU8cSaXKLI4SZEo5A45kQWps4YX8rSCEGOwifTdHwmvp7L8zX4O_jC0LXKYU5sJ2pXW9oj301icvoVeZbsXf8KKWsUna4OKTQ6szjyf36jZGs-Tr5g_76P48OD08_jsM8qEFrBo0UYC5l5FO9xqaSRXhRCuLTIrZdJmgtXGhUVSGoMVzYSvCi4j6MyK00iuVU8NQm2uw4bIkEpM4KNTwfTb99vd3Vw9RNtpleekN8LEpTBU0elu43AMU0O0SKk07AozP9ZDderefl_otsueIeP4VHPVNl-Z1qbsOarJ6D2f85qR_muPbusiHE2vmF0P53VJbvuQlcwSskVmupi5hmy8yUCbJ7C2b3A9AxGVV35F8ByZTLpeIFKUyJsuSrRCJxFJukc0qcoAD6AoG0fmZwSZMx0q1BUqjvgNAKnW-B0HsCHVZ3-5-4s_Rax1Vf2UlM4bXpe1PpqrlE0TLAeirBM8gC2B-x1P5IbfWt3AbxZvcYxSAcrpvL1Estwuk6PPZ8G8Lzrs9VHJTkFWlVy6-7GX8OD8enJsT6eTI9ewsOYbKT1eNyG0WK-9K-Q-iyKnd7eGPy4bxO_AflwDwo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Amlodipine+increases+risk+of+primary+open-angle+glaucoma&rft.jtitle=Rinsh%C5%8D+k%C5%8Dketsuatsu+%3D+Clinical+hypertension&rft.au=Lehrer%2C+Steven&rft.au=Rheinstein%2C+Peter+H&rft.date=2024-11-01&rft.pub=BioMed+Central&rft.issn=1342-2154&rft.volume=30&rft.spage=1&rft_id=info:doi/10.1186%2Fs40885-024-00290-9 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2056-5909&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2056-5909&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2056-5909&client=summon |